Background: A new tool for the drug delivery is based on the use of Mesenchymal Stromal Cells
(MSCs) loaded in vitro with anti-cancer drugs. Unfortunately, the restricted lifespan of MSCs represents a significant
limitation to produce them in high amounts and for long time studies. Immortalized MSCs from adipose
tissue (hASCs) have been generated as good source of cells with stable features. These cells could improve the
development of standardized procedures for both in vitro and preclinical studies. Furthermore they facilitate
procedures for preparing large amounts of secretome containing microvesicles (MVs).
Method: We used human adipose tissue derived MSCs immortalized with hTERT+SV40 (TS) genes and transfected
with GFP (hASCs-TS/GFP+). This line was investigated for its ability to uptake and release anticancer
drugs. Microvesicles associated to paclitaxel (MVs/PTX) were isolated, quantified, and tested on pancreatic
Results: The line hASCs-TS/GFP+ maintained the main mesenchymal characters and was able to uptake and
release, in active form, both paclitaxel and gemcitabine. From paclitaxel loaded hASCs-TS/GFP+ cells were
isolated microvesicles in sufficient amount to inhibit “in vitro” the proliferation of pancreatic tumor cells.
Conclusion: Our study suggests that human immortalized MSCs could be used for a large scale production of
cells for mediated drug delivery. Moreover, the secretion of drug-associated MVs could represent a new way for
producing new drug formulation by “biogenesis”. In the context of the “advanced cell therapy procedure”, the
MVs/PTX production would use less resource and time and it could possibly contribute to simplification of